Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus

Wanwisa Dejnirattisai; Piyada Supasa; Wiyada Wongwiwat; Alexander Rouvinski; Giovanna Barba-Spaeth; Thaneeya Duangchinda; Anavaj Sakuntabhai; Van Mai Cao-Lormeau; Prida Malasit; Felix A. Rey; Juthathip Mongkolsapaya; Gavin R. Screaton

doi:10.1038/ni.3515

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus

Wanwisa Dejnirattisai, Piyada Supasa, Wiyada Wongwiwat, Alexander Rouvinski, Giovanna Barba-Spaeth, Thaneeya Duangchinda, Anavaj Sakuntabhai, Van Mai Cao-Lormeau, Prida Malasit, Felix A. Rey, Juthathip Mongkolsapaya, Gavin R. Screaton^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

679 Scopus citations

Abstract

Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barré syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.

Original language	American English
Pages (from-to)	1102-1108
Number of pages	7
Journal	Nature Immunology
Volume	17
Issue number	9
DOIs	https://doi.org/10.1038/ni.3515
State	Published - 19 Aug 2016
Externally published	Yes

Bibliographical note

Funding Information:
We thank Armed Forces Research Institute of Medical Sciences, Thailand for Vero cells, C6/36 cells, mAb 4G2 to DENV envelope protein, and viruses DENV- 1, DENV-2 and DENV-3; and M. Nguyen-De Bernon for technical assistance. Supported by the Medical Research Council, UK, the Wellcome Trust, UK (G.R.S.), the National Institute for Health Research Biomedical Research Centre, Funding Scheme, European Commission Seventh Framework Programme (FP7/2007- 2013) for the DENFREE project (under grant agreement 282 378), Laboratory of Excellence Integrative Biology of Emerging Infectious Diseases (ANR-10-LABX- 62-IBEID to F.A.R.), Agence Nationale de la Recherche (FlaviStem/I1378 to F.A.R.) and the Thailand Research Fund through the Royal Golden Jubilee PhD (P.S. and J.M.).

Publisher Copyright:
© 2016 Nature America, Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/ni.3515

Cite this

Dejnirattisai, W., Supasa, P., Wongwiwat, W., Rouvinski, A., Barba-Spaeth, G., Duangchinda, T., Sakuntabhai, A., Cao-Lormeau, V. M., Malasit, P., Rey, F. A., Mongkolsapaya, J., & Screaton, G. R. (2016). Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nature Immunology, 17(9), 1102-1108. https://doi.org/10.1038/ni.3515

@article{6c9fa0ad507a427c89fe18f44981ba59,

title = "Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus",

abstract = "Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barr{\'e} syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.",

author = "Wanwisa Dejnirattisai and Piyada Supasa and Wiyada Wongwiwat and Alexander Rouvinski and Giovanna Barba-Spaeth and Thaneeya Duangchinda and Anavaj Sakuntabhai and Cao-Lormeau, {Van Mai} and Prida Malasit and Rey, {Felix A.} and Juthathip Mongkolsapaya and Screaton, {Gavin R.}",

note = "Funding Information: We thank Armed Forces Research Institute of Medical Sciences, Thailand for Vero cells, C6/36 cells, mAb 4G2 to DENV envelope protein, and viruses DENV- 1, DENV-2 and DENV-3; and M. Nguyen-De Bernon for technical assistance. Supported by the Medical Research Council, UK, the Wellcome Trust, UK (G.R.S.), the National Institute for Health Research Biomedical Research Centre, Funding Scheme, European Commission Seventh Framework Programme (FP7/2007- 2013) for the DENFREE project (under grant agreement 282 378), Laboratory of Excellence Integrative Biology of Emerging Infectious Diseases (ANR-10-LABX- 62-IBEID to F.A.R.), Agence Nationale de la Recherche (FlaviStem/I1378 to F.A.R.) and the Thailand Research Fund through the Royal Golden Jubilee PhD (P.S. and J.M.). Publisher Copyright: {\textcopyright} 2016 Nature America, Inc.",

year = "2016",

month = aug,

day = "19",

doi = "10.1038/ni.3515",

language = "American English",

volume = "17",

pages = "1102--1108",

journal = "Nature Immunology",

issn = "1529-2908",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus

AU - Dejnirattisai, Wanwisa

AU - Supasa, Piyada

AU - Wongwiwat, Wiyada

AU - Rouvinski, Alexander

AU - Barba-Spaeth, Giovanna

AU - Duangchinda, Thaneeya

AU - Sakuntabhai, Anavaj

AU - Cao-Lormeau, Van Mai

AU - Malasit, Prida

AU - Rey, Felix A.

AU - Mongkolsapaya, Juthathip

AU - Screaton, Gavin R.

N1 - Funding Information: We thank Armed Forces Research Institute of Medical Sciences, Thailand for Vero cells, C6/36 cells, mAb 4G2 to DENV envelope protein, and viruses DENV- 1, DENV-2 and DENV-3; and M. Nguyen-De Bernon for technical assistance. Supported by the Medical Research Council, UK, the Wellcome Trust, UK (G.R.S.), the National Institute for Health Research Biomedical Research Centre, Funding Scheme, European Commission Seventh Framework Programme (FP7/2007- 2013) for the DENFREE project (under grant agreement 282 378), Laboratory of Excellence Integrative Biology of Emerging Infectious Diseases (ANR-10-LABX- 62-IBEID to F.A.R.), Agence Nationale de la Recherche (FlaviStem/I1378 to F.A.R.) and the Thailand Research Fund through the Royal Golden Jubilee PhD (P.S. and J.M.). Publisher Copyright: © 2016 Nature America, Inc.

PY - 2016/8/19

Y1 - 2016/8/19

N2 - Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barré syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.

AB - Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barré syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.

UR - http://www.scopus.com/inward/record.url?scp=84976292755&partnerID=8YFLogxK

U2 - 10.1038/ni.3515

DO - 10.1038/ni.3515

M3 - Article

C2 - 27339099

AN - SCOPUS:84976292755

SN - 1529-2908

VL - 17

SP - 1102

EP - 1108

JO - Nature Immunology

JF - Nature Immunology

IS - 9

ER -

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this